90,688 results match your criteria Bladder Cancer


Therapeutic significance of ARID1A mutation in bladder cancer.

Neoplasia 2022 Jun 21;31:100814. Epub 2022 Jun 21.

Department of Internal Medicine I, Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, Medical Centre - University of Freiburg, Freiburg, Baden-Württemberg, Germany; German Cancer Consortium (DKTK), Partner Site Freiburg, and German Cancer Research Center (DKFZ), Heidelberg, Baden-Württemberg, Germany; Signalling Research Centre BIOSS, University of Freiburg, Freiburg, Baden-Württemberg, Germany; Comprehensive Cancer Center Freiburg (CCCF), Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Baden-Württemberg, Germany. Electronic address:

Bladder cancer (BC) develops from the tissues of the urinary bladder and is responsible for nearly 200,000 deaths annually. This review aims to integrate knowledge of recently discovered functions of the chromatin remodelling tumour suppressor protein ARID1A in bladder urothelial carcinoma with a focus on highlighting potential new avenues for the development of personalised therapies for ARID1A mutant bladder tumours. ARID1A is a component of the SWI/SNF chromatin remodelling complex and functions to control many important biological processes such as transcriptional regulation, DNA damage repair (DDR), cell cycle control, regulation of the tumour microenvironment and anti-cancer immunity. Read More

View Article and Full-Text PDF

Fine particulate matter induces METTL3-mediated mA modification of BIRC5 mRNA in bladder cancer.

J Hazard Mater 2022 Jun 8;437:129310. Epub 2022 Jun 8.

Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 211166, China; Department of Genetic Toxicology, The Key Laboratory of Modern Toxicology of Ministry of Education, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing 211166, China. Electronic address:

Long-term exposure to fine particulate matter (PM) is reportedly related to a variety of cancers including bladder cancer. However, little is known about the biological mechanism underlying this association. In the present study, PM exposure was significantly associated with increased levels of mA modification in bladder cancer patients and bladder cells. Read More

View Article and Full-Text PDF

Nonmuscle-invasive bladder cancer, old problems, new insights.

Curr Opin Urol 2022 Jul;32(4):352-357

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Purpose Of Review: Nonmuscle-invasive bladder cancer (NMIBC) is the most frequent bladder cancer and represents around 75% of bladder cancers. This review will discuss known challenges and recent advances in staging, grading and treatment stratification based on pathology.

Recent Findings: Pathological staging and grading in NMIBC remains challenging and different techniques exist. Read More

View Article and Full-Text PDF

Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update.

Curr Opin Urol 2022 Jun 27. Epub 2022 Jun 27.

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Purpose Of Review: To critically analyze the oncological outcomes and safety profile of device-assisted intravesical chemotherapy studies reported in 2021. Studies were considered eligible if they included patients with nonmuscle invasive blood cancer (NMIBC), had a prospective or retrospective design, included at least 10 patients, were published in 2021, and assessed the oncological impact of device-assisted intravesical chemotherapy and/or reported standardized adverse effects (AEs).

Recent Findings: Eight new studies reported oncological outcomes after hyperthermic intravesical chemotherapy (HIVEC). Read More

View Article and Full-Text PDF

Validation of a scoring system to predict bladder dysfunction after laparoscopic rectal cancer surgery.

Langenbecks Arch Surg 2022 Jun 24. Epub 2022 Jun 24.

Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 29 Saemunan-ro, Jongno-gu, Seoul, 03181, Republic of Korea.

Purpose: A recent trend in  urinary catheter management in patients who underwent laparoscopic rectal cancer surgery is early removal. However, some patients develop bladder dysfunction and require urinary re-catheterization. In 2016, a scoring system to predict bladder dysfunction after laparoscopic rectal cancer surgery was developed in our institution. Read More

View Article and Full-Text PDF

Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer.

Cancer Immunol Immunother 2022 Jun 24. Epub 2022 Jun 24.

Experimental Developmental Therapeutics (EDT) Program, Mays Cancer Center at UT Health MD Anderson, San Antonio, TX, USA.

Purpose: Repeated instillations of bacillus Calmette et Guérin (BCG) are the gold standard immunotherapeutic treatment for reducing recurrence for patients with high-grade papillary non-muscle invasive bladder cancer (NMIBC) and for eradicating bladder carcinoma-in situ. Unfortunately, some patients are unable to tolerate BCG due to treatment-associated toxicity and bladder removal is sometimes performed for BCG-intolerance. Prior studies suggest that selectively delipidated BCG (dBCG) improves tolerability of intrapulmonary delivery reducing tissue damage and increasing efficacy in preventing Mycobacterium tuberculosis infection in mice. Read More

View Article and Full-Text PDF

Heterogeneity Analysis of Bladder Cancer Based on DNA Methylation Molecular Profiling.

Front Oncol 2022 7;12:915542. Epub 2022 Jun 7.

College of Information and Computer Engineering, Northeast Forestry University, Harbin, China.

Bladder cancer is a highly complex and heterogeneous malignancy. Tumor heterogeneity is a barrier to effective diagnosis and treatment of bladder cancer. Human carcinogenesis is closely related to abnormal gene expression, and DNA methylation is an important regulatory factor of gene expression. Read More

View Article and Full-Text PDF

The origin of bladder cancer from mucosal field effects.

iScience 2022 Jul 7;25(7):104551. Epub 2022 Jun 7.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Whole-organ mapping was used to study molecular changes in the evolution of bladder cancer from field effects. We identified more than 100 dysregulated pathways, involving immunity, differentiation, and transformation, as initiators of carcinogenesis. Dysregulation of interleukins signified the involvement of inflammation in the incipient phases of the process. Read More

View Article and Full-Text PDF

Chemotherapy with a TP Regimen in Combination with Stereotactic Radiotherapy Could Significantly Optimize the Clinical Efficacy of NSCLC Treatment.

Evid Based Complement Alternat Med 2022 14;2022:8495452. Epub 2022 Jun 14.

Department of Respiratory and Critical Care Medicine, Shiyan Taihe Hospital, Shiyan 442000, Hubei, China.

The changes in lifestyle and bad living habits have a significant impact on the health of people, resulting in an increasing prevalence of lung cancer. The most prevalent kind of lung cancer is nonsmall cell lung cancer (NSCLC), which accounts for around 80% of all cases. Chemotherapy is a common treatment method in clinical practice with certain negative effects. Read More

View Article and Full-Text PDF

Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-β signalling pathway.

Bioengineered 2022 Jun;13(6):14282-14298

Clinical Laboratory, First Affiliated Hospital of Dalian Medical University, Dalian, People's Republic of China.

Bladder cancer (BC) is one of the most common urinary tract malignancies and is the tenth most common cancer globally. Alpha-2 Heremans Schmid Glycoprotein (AHSG) is a multifunctional protein that plays different roles in the progression of multiple tumors. However, the role and mechanism of AHSG in the development and progression of BC are unknown. Read More

View Article and Full-Text PDF

Phase I Clinical Trial Using [Tc]Tc-1-thio-D-glucose for Diagnosis of Lymphoma Patients.

Pharmaceutics 2022 Jun 15;14(6). Epub 2022 Jun 15.

Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, 634050 Tomsk, Russia.

Similar to [F]-FDG, [Tc]Tc-1-thio-D-glucose ([Tc]Tc-TG) also binds to GLUT receptors. The aim of this Phase I study was to evaluate the safety, biodistribution and dosimetry of [Tc]Tc-TG. Twelve lymphoma patients were injected with 729 ± 102 MBq [Tc]Tc-TG. Read More

View Article and Full-Text PDF

Novel Antimicrobial Strategies to Prevent Biofilm Infections in Catheters after Radical Cystectomy: A Pilot Study.

Life (Basel) 2022 May 27;12(6). Epub 2022 May 27.

Andrological and Urogynecological Clinic, Santa Maria Terni Hospital, University of Perugia, 05100 Terni, Italy.

Catheter-associated infections in bladder cancer patients, following radical cystectomy or ureterocutaneostomy, are very frequent, and the development of antibiotic resistance poses great challenges for treating biofilm-based infections. Here, we characterized bacterial communities from catheters of patients who had undergone radical cystectomy for muscle-invasive bladder cancer. We evaluated the efficacy of conventional antibiotics, alone or combined with the human ApoB-derived antimicrobial peptide r(P)ApoB, to treat ureteral catheter-colonizing bacterial communities on clinically isolated bacteria. Read More

View Article and Full-Text PDF

En-bloc Laser Resection of Bladder Tumors: Where Are We Now?

J Clin Med 2022 Jun 16;11(12). Epub 2022 Jun 16.

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, 80130 Naples, Italy.

Transurethral resection of bladder tumors (TURBT) is a crucial procedure in the management of bladder cancer [... Read More

View Article and Full-Text PDF

Antitumor Effects of Orally Administered Rare Sugar D-Allose in Bladder Cancer.

Int J Mol Sci 2022 Jun 17;23(12). Epub 2022 Jun 17.

Department of Urology, Faculty of Medicine, Kagawa University, 1750-1 Ikenobe, Miki-cho 761-0793, Japan.

D-allose is a rare sugar that has been reported to up-regulate thioredoxin-interacting protein (TXNIP) expression and affect the production of intracellular reactive oxygen species (ROS). However, the antitumor effect of D-allose is unknown. This study aimed to determine whether orally administered D-allose could be a candidate drug against bladder cancer (BC). Read More

View Article and Full-Text PDF

Hypomethylation of Gene Promoter Is Associated with Malignant Phenotype in Urinary Bladder Cancer.

Int J Mol Sci 2022 Jun 10;23(12). Epub 2022 Jun 10.

Department of Molecular Pathology, Nara Medical University, 840 Shijo-cho, Kashihara 634-8521, Nara, Japan.

The tight junction (TJ) protein claudin-4 (CLDN4) is overexpressed in bladder urothelial carcinoma (BUC) and correlates with cancer progression. However, the mechanism of CLDN4 upregulation and promotion of malignant phenotype is not clear. Here, we analyzed 157 cases of BUC and investigated the hypomethylation of CpG island in the promoter DNA and its correlation with cancer progression. Read More

View Article and Full-Text PDF

5-Aminolevulinic Acid-Induced Protoporphyrin IX Fluorescence Imaging for Tumor Detection: Recent Advances and Challenges.

Int J Mol Sci 2022 Jun 9;23(12). Epub 2022 Jun 9.

Department of Pathology and Cell Regulation, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 465 Kajii-cho Kamigyo-ku, Kyoto 602-8566, Japan.

5-Aminolevulinic acid (5-ALA) is a natural amino acid and a precursor of heme and chlorophyll. Exogenously administered 5-ALA is metabolized into protoporphyrin IX (PpIX). PpIX accumulates in cancer cells because of the low activity of ferrochelatase, an enzyme that metabolizes PpIX to heme. Read More

View Article and Full-Text PDF

Association of Hypertension and Organ-Specific Cancer: A Meta-Analysis.

Healthcare (Basel) 2022 Jun 9;10(6). Epub 2022 Jun 9.

Department of Biomedical Engineering, University of Wisconsin, Milwaukee, WI 53211, USA.

Hypertension and cancer are two of the leading global causes of death. Hypertension, known as chronic high blood pressure, affects approximately 45% of the American population and is a growing condition in other parts of the world, particularly in Asia and Europe. On the other hand, cancer resulted in approximately 10 million deaths in 2020 worldwide. Read More

View Article and Full-Text PDF

Robust Prediction of Prognosis and Immunotherapy Response for Bladder Cancer through Machine Learning Algorithm.

Genes (Basel) 2022 Jun 16;13(6). Epub 2022 Jun 16.

Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200080, China.

The important roles of machine learning and ferroptosis in bladder cancer (BCa) are still poorly understood. In this study, a comprehensive analysis of 19 ferroptosis-related genes (FRGs) was performed in 1322 patients with BCa from four independent patient cohorts and a pan-cancer cohort of 9824 patients. Twelve FRGs were selected through machine learning algorithm to construct the prognosis model. Read More

View Article and Full-Text PDF

A Survey on Deep Learning for Precision Oncology.

Diagnostics (Basel) 2022 Jun 17;12(6). Epub 2022 Jun 17.

Graduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 106335, Taiwan.

Precision oncology, which ensures optimized cancer treatment tailored to the unique biology of a patient's disease, has rapidly developed and is of great clinical importance. Deep learning has become the main method for precision oncology. This paper summarizes the recent deep-learning approaches relevant to precision oncology and reviews over 150 articles within the last six years. Read More

View Article and Full-Text PDF

Modified Immunoscore Improves Prediction of Survival Outcomes in Patients Undergoing Radical Cystectomy for Bladder Cancer-A Retrospective Digital Pathology Study.

Diagnostics (Basel) 2022 Jun 1;12(6). Epub 2022 Jun 1.

Department of Urology, University Hospital of Zurich, University of Zurich, 8091 Zurich, Switzerland.

To evaluate the prognostic value of a modified Immunoscore (mIS) in a cohort of bladder cancer (BC) patients undergoing radical cystectomy (RC), two tissue microarrays of 159 BC patients were immunohistochemically stained for CD3/CD8/FOXP3 and CD45RO to detect Tumor-Infiltrating Lymphocytes (TIL). To predict progression free survival (PFS) and cancer specific survival (CSS), a predictive model cumulatively incorporating all four components was constructed and labeled as mIS. Patients were stratified into two risk groups; "high mIS/favorable risk" and "low mIS/unfavorable risk". Read More

View Article and Full-Text PDF

Relevance of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 Protein Expression to Bladder Cancer Malignancy.

Biomolecules 2022 Jun 6;12(6). Epub 2022 Jun 6.

Department of Urology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.

We evaluated the effect of A Disintegrin and Metalloproteinase Domain-Containing (ADAM)9 protein on exacerbation in bladder cancer KK47 and T24. First, we knocked down ADAM9 and investigated cell proliferation, migration, cell cycle, and the epithelial-mesenchymal transition (EMT)-related proteins expression in vitro. We then investigated the expression level of ADAM9 in clinical urine cytology samples and the Cancer Genome Atlas (TCGA) data. Read More

View Article and Full-Text PDF

Comprehensive Landscape of RRM2 with Immune Infiltration in Pan-Cancer.

Cancers (Basel) 2022 Jun 14;14(12). Epub 2022 Jun 14.

Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, China.

As a crucial subunit of ribonucleotide reductase, RRM2 plays a significant part in DNA synthesis. This study aimed to elucidate the comprehensive landscape of RRM2 in human cancers. With different bioinformatics platforms, we investigated the expression pattern, prognostic significance, mutational landscapes, gene interaction network, signaling pathways and immune infiltration of RRM2 in tumors. Read More

View Article and Full-Text PDF

Acetyl-CoA Synthetase 2 as a Therapeutic Target in Tumor Metabolism.

Cancers (Basel) 2022 Jun 12;14(12). Epub 2022 Jun 12.

Institute of Oncology, Affiliated Hospital of Jiangsu University, 438 Jiefang Road, Zhenjiang 212001, China.

Acetyl-CoA Synthetase 2 (ACSS2) belongs to a member of the acyl-CoA short-chain synthase family, which can convert acetate in the cytoplasm and nucleus into acetyl-CoA. It has been proven that ACSS2 is highly expressed in glioblastoma, breast cancer, liver cancer, prostate cancer, bladder cancer, renal cancer, and other tumors, and is closely related to tumor stage and the overall survival rate of patients. Accumulating studies show that hypoxia and a low serum level induce ACSS2 expression to help tumor cells cope with this nutrient-poor environment. Read More

View Article and Full-Text PDF

Efficacy of Vinflunine for Patients with Metastatic Urothelial Cancer after Immune Checkpoint Inhibitor Pretreatment-A Retrospective Multicenter Analysis.

Cancers (Basel) 2022 Jun 9;14(12). Epub 2022 Jun 9.

Department of Urology, University Hospital Ulm, 89081 Ulm, Germany.

Background: Immune checkpoint inhibitors (ICI) are standard of care in patients with metastatic urothelial carcinoma (mUC) ineligible for cisplatin, and as second-line therapy after platinum-based chemotherapy. To date, few data exist about the efficacy of the former second-line chemotherapeutic agent vinflunine after the failure of sequential platinum-based chemotherapy and ICI treatment. The aim of this analysis was to examine the efficacy of vinflunine in a post-ICI third- or later-line setting. Read More

View Article and Full-Text PDF

Rac1 as a Target to Treat Dysfunctions and Cancer of the Bladder.

Biomedicines 2022 Jun 8;10(6). Epub 2022 Jun 8.

OncoWitan, Scientific Consulting Office, 59290 Lille (Wasquehal), France.

Bladder pathologies, very common in the aged population, have a considerable negative impact on quality of life. Novel targets are needed to design drugs and combinations to treat diseases such as overactive bladder and bladder cancers. A promising new target is the ubiquitous Rho GTPase Rac1, frequently dysregulated and overexpressed in bladder pathologies. Read More

View Article and Full-Text PDF

Effective Radiosensitization of Bladder Cancer Cells by Pharmacological Inhibition of DNA-PK and ATR.

Biomedicines 2022 May 30;10(6). Epub 2022 May 30.

Institute of Pathology, RWTH Aachen University, 52074 Aachen, Germany.

This study aims at analyzing the impact of the pharmacological inhibition of DNA damage response (DDR) targets (DNA-PK and ATR) on radiosensitization of bladder cancer cell lines of different molecular/histological subtypes. Applying DNA-PK (AZD7648) and ATR (Ceralasertib) inhibitors on SCaBER, J82 and VMCUB-1 bladder cancer cell lines, we revealed sensitization upon ionizing radiation (IR), i.e. Read More

View Article and Full-Text PDF

Long-term urological complications after conservative local treatment (surgery and brachytherapy) in children with bladder-prostate rhabdomyosarcoma: A single-team experience.

Pediatr Blood Cancer 2022 Aug 6;69(8):e29532. Epub 2022 Jan 6.

Department of Pediatric Surgery, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Le Kremlin-Bicêtre, France.

Background: Outcome of children with bladder-prostate rhabdomyosarcoma (RMS) has improved with multimodal therapies, including surgery and/or radiotherapy for local treatment. Our aim was to report long-term urological complications after a conservative approach combining conservative surgery and brachytherapy.

Patients And Methods: Eighty-six patients, free of disease, were retrospectively reviewed. Read More

View Article and Full-Text PDF

Error Detectability of Isodose Volumes as ROIs in Prostate Intensity-modulated RT QA.

In Vivo 2022 Jul-Aug;36(4):1887-1895

Department of Radiology, Hyogo Medical University, Nishinomiya, Japan.

Background/aim: To evaluate the quality of error detectability with a three-dimensional verification system using isodose volumes as regions of interest (ROIs) in quality assurance (QA) of intensity-modulated radiation therapy.

Patients And Methods: Treatment plans with four types of intentional errors were created from the data of 20 patients with localized prostate cancer. These plans underwent QA using the three-dimensional verification system. Read More

View Article and Full-Text PDF

Assessment of Feasibility of Robot-assisted Radical Cystectomy in Patients With Advanced Bladder Cancer Treated With Maintenance Hemodialysis Therapy.

In Vivo 2022 Jul-Aug;36(4):1801-1806

Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.

Background/aim: To clarify the perioperative and oncological outcomes of robot-assisted radical cystectomy (RARC) in advanced bladder cancer (BC) patients treated with maintenance hemodialysis (HD) therapy.

Patients And Methods: We retrospectively evaluated patients receiving HD therapy who had undergone RARC or open radical cystectomy (ORC) for BC between April 1988 and December 2021 at two affiliated institutions. We compared the surgical outcomes and survival after radical cystectomy between patients treated with RARC and those treated with ORC. Read More

View Article and Full-Text PDF

p53 gene delivery via a recombinant Salmonella enterica Typhimurium leads to human bladder carcinoma cell death in vitro.

Lett Appl Microbiol 2022 Jun 23. Epub 2022 Jun 23.

Department of Genetics, Evolution, Microbiology, and Immunology, Tropical Disease Laboratory, Institute of Biology, University of Campinas - UNICAMP, 13083-970, Campinas, SP, Brazil.

Numerous studies have attempted to restore the function of the tumour suppressor p53 as an anticancer strategy through gene delivery. However, most studies employed non-bacterial vectors to deliver p53. Various facultative and obligate anaerobic bacteria have been proposed as vectors because of their intrinsic tumour targeting ability and antitumour activity. Read More

View Article and Full-Text PDF